



ASX Announcement

1 June 2017

Creso first to export high quality medicinal cannabis from Switzerland into Asia Pacific and LATAM

Highlights:

- **LOI signed with leading Swiss-based medicinal cannabis producer Cannapharm**
- **Creso to capitalise on first mover advantage to be exclusive distributor of highest quality Swiss-grade medicinal cannabis products into Asia Pacific and LATAM markets**
- **Cannapharm manufactures medicinal cannabis to highest pharmaceutical and GMP standards in the highly regulated Swiss market**
- **Agreement initially covers seven countries in Asia Pacific and LATAM but can be expanded to other countries or regions**
- **Partnership will further enhance Creso's market leadership position in the rapidly growing industry**

Creso Pharma Limited (ASX:CPH, "Creso" or the "Company") is pleased to announce that it has signed a binding Letter of Intent (LOI) with Cannapharm AG to provide patients in Asia Pacific and Latin America (LATAM) access to top quality medicinal cannabis products from Switzerland to address a variety of conditions as approved by prescribing physicians under relevant local legislations.

Both parties will work towards formalising the collaboration agreement where Cannapharm will grant Creso the exclusive rights to import, store, transport, market, distribute, use and sell Cannapharm's medicinal cannabis products in seven countries in Asia Pacific and LATAM. These countries include Australia, New Zealand, China, Brazil, Chile, Colombia and Mexico. The agreement allows for both parties to expand the exclusivity to include additional countries or regions.

This is a significant commercial partnership as it will give Creso a first-mover advantage in exporting best-in-class pharmaceutical-grade medicinal cannabis products into these new markets for use to address a range of serious diseases.

Cannapharm is a Swiss-based producer of fully Good Manufacturing Practices (GMP) certified medicinal cannabis. It has over 15 years of experience manufacturing products that meet the highest pharmaceutical and GMP standards in the tightly regulated Swiss market.

Creso will operate in strict compliance with all applicable legislations and regulations in the relevant countries.

"This partnership with Cannapharm significantly builds on our position within the Australian market as a leading medicinal cannabis company that intends to supply the Australian market with high quality medicinal cannabis products. Cannapharm is the perfect partner and strategic fit for Creso given their

For personal use only



expertise in the cultivation, manufacture and distribution of cannabis derived therapeutic products,” said the Co-Founder and Group Chief Executive Officer of Creso Pharma, Dr. Miri Halperin Wernli.

“I am excited that Creso can play a major role in improving patient outcomes and contribute to a better quality of life through our medicinal cannabis products in the different territories, which will strengthen our overall franchise in the whole cannabis space. This agreement will further bolster Creso’s strong position in the various applications of cannabis and hemp-derived therapeutic solutions.”

Dr. Gian Trepp, Marketing and Commercial Director in Creso Switzerland said: “We are excited to bring top quality Swiss medicinal cannabis products into various countries where regulatory schemes are in place to leverage the Swiss pharmaceutical expertise to the benefit of patients.”

---END---

Investor Enquiries:

Brendon Lau
M: 0409 341 613
E: brendon.lau@mcpartners.com.au

Media Enquiries:

Elise Hughan
M: 0458 855 500
E: elise.hughan@mcpartners.com.au

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 0000

About Creso Pharma

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products. It is the leader in cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

For personal use only



About Cannapharm

Cannapharm is a Swiss-based producer of fully Good Manufacturing Practices (GMP) certified medicinal cannabis, licensed by the Swiss Agency for Therapeutic Products (Swissmedic) for the manufacturing and wholesale of medicines with over 15 years of experience producing products that meet the highest pharmaceutical and GMP standards in the tightly regulated Swiss market.

For personal use only